ASIT Biotech's Novel Grass Allergy Product Needs Second Phase III Study
Executive Summary
Belgium’s ASIT biotech hopes to succeed in the difficult allergy market with a more focused Phase III study of its grass pollen allergy product, after its first Phase III study showed that the product significantly improved symptoms, but not to an extent to satisfy regulators.